Following ASCO 2023, experts in oncology review recent data from the CLEAR and CONTACT-03 clinical trials in the metastatic renal cell carcinoma space.
In Real-World Analyses, Apalutamide Delivers Quicker Responses in Prostate Cancer
June 15th 2024Benjamin Lowentritt, MD, discussed findings from real-world analyses looking at enzalutamide or abiraterone vs apalutamide in patients with metastatic castration-sensitive prostate cancer.
Read More